(HealthDay News) — The risk of major adverse cardiovascular events (MACE) is increased with renal function decline, according to a study published online in Diabetes Care.
Stéphanie Ragot, PharmD, PhD, from INSERM CIC 1402 in Poitiers, France, and colleagues examined the correlation between renal function trajectories and the occurrence of a cardiovascular (CV) event in patients with type 2 diabetes from a discovery cohort (1,040 participants) and replication cohort.
The researchers found that over 6.3 years of follow-up there was an annual estimated glomerular filtration rate (eGFR) decline and an annual serum creatinine (SCr) increase that was significantly greater in patients with versus those without MACE (P < 0.0001 for both). Patients with MACE had significantly steeper median annual individual slopes; patients with rapid decline in eGFR had adjusted risk of MACE that was 4.11 times higher. Significant additive information to help explain the occurrence of MACE for both SCr and eGFR was seen with consideration of renal function trajectories. Results were confirmed in the replication cohort.
“Renal function decline was associated with a higher risk of MACE,” the authors write. “The pattern of renal function decline, beyond baseline kidney function, is an independent factor of CV risk.”
Several authors disclosed financial ties to the pharmaceutical industry.